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Abstract
Summary We investigated prevention trends and predictors
for osteoporosis prevention in long term corticosteroid users.
The use of bisphosphonates increased from 2001 to 2005.
Longer duration of corticosteroid use and DMARD use were
predictors for receiving prevention. Females appear reason-
ably well treated; however, men require more attention.
Introduction Previous studies have shown that long-term
corticosteroid users are undertreated for osteoporosis
prevention. Our aim was to identify prevention trends in
long-term corticosteroid users from 2001–2005 in The
Netherlands and to identify predictors for bisphosphonate
prophylaxis.
Methods Pharmacy dispensing data were used from 9
community pharmacies. All oral corticosteroid doses were
converted to “prednisolone equivalents”. We then identified
long-term (≥90 days) corticosteroid episodes, which re-
quired bisphosphonate prophylaxis as per 2002 Dutch
guidelines; Multivariate logistic regression was used to
identify predictors for receiving prevention.
Results We identified 615 different corticosteroid patients
requiring prophylaxis. From 2001–2005 the use of
bisphosphonates increased from 38% to 54% (p=0.001). In
2005 females were prescribed more bisphosphonates than
males (61% vs. 39%; p=0.002), or any treatment (72% vs.
45%; p<0.001). Multivariate analysis showed that longer
duration of corticosteroid use and disease-modifying anti-
rheumatic drug (DMARD) use were independent predictors
of bisphosphonate use. Use of respiratory medication was a
negative predictor of bisphosphonate use.
Conclusion There has been a significant increase in
osteoporosis prophylaxis in a population at high risk for
osteoporosis/fractures. In particular, females appear reason-
ably well treated; however, men are still not receiving
prevention to the same degree as women.
Keywords Corticosteroids . Osteoporosis .
Prescribing patterns . Prevention . The Netherlands
Introduction
Corticosteroid-induced osteoporosis (CIOP) is the most
common type of secondary osteoporosis with up to 50% of
chronic corticosteroid users sustaining fractures [1, 2].
Numerous international studies have demonstrated that
osteoporosis is underrecognised and undertreated in cortico-
steroid users [3–5]. In the Netherlands, national specialist
guidelines (2002) recommend preventive therapy for those
on ≥7.5 mg for longer than 3 months [6]. Curtis et al. [3]
recently showed that despite significant increases in osteo-
porosis prevention in long-term corticosteroid users, absolute
rates remain low in the USA. From a European perspective,
Osteoporos Int (2007) 18:1429–1433
DOI 10.1007/s00198-007-0345-9
M. Duyvendak :M. Naunton : J. R. B. J. Brouwers
Department of Clinical Pharmacy,
Tjongerschans Hospital,
Heerenveen, The Netherlands
M. Duyvendak (*) :M. Naunton : J. Atthobari :
P. B. van den Berg : J. R. B. J. Brouwers
Department of Pharmacotherapy and Pharmaceutical Care,
University of Groningen,
Antonius Deusinglaan 1,
9713 AV Groningen, The Netherlands
e-mail: mduyvendak@tjongerschans.nl
M. Naunton
School of Science, Charles Darwin University,
Northern Territory, Australia
J. Atthobari : P. B. van den Berg : J. R. B. J. Brouwers
Groningen University Institute for Drug Exploration (GUIDE),
Groningen, The Netherlands
we are unaware of any published research investigating the
longitudinal patterns in osteoporosis prescribing.
The aim of this study was to (a) identify prevention
trends in long-term corticosteroid users who required
osteoporosis/fracture prophylaxis as per Dutch 2002 guide-
lines from July 2001-December 2005 (b) identify predictors
for receiving bisphosphonate prophylaxis.
Methods
Population
We used pharmacy dispensing data (deidentified) from nine
community pharmacies spread over four cities/towns in the
northern part of The Netherlands (catchment population
approximately 125,000). To assess the prevalence of
prophylaxis for CIOP between July 2001 and December
2005, we determined for each half year period whether a
patient required prophylaxis with bisphosphonates during
that period and whether they were prescribed a bisphospho-
nate or other type of prevention.
Inclusion criteria
We identified all patients (>18 years) receiving oral
corticosteroids for ≥90 days requiring prophylaxis accord-
ing to Dutch (2002) guidelines [6] during the period July
2001 to December 2005. Specifically, the guidelines
recommend that men ≥70 years old and postmenopausal
women who receive >7.5 mg–15 mg/day of prednisolone
(or equivalent) or >15 mg/day prednisolone (or equivalent)
independent of age and gender should receive bisphospho-
nate treatment independent of BMD. The guidelines state
that calcium and/or vitamin D alone is insufficient
prophylaxis. A postmenopausal status was assumed for
women aged ≥55 years.
Qualifying corticosteroid medications
Corticosteroid episodes were identified by selecting all
prescriptions with a maximum of 90 days between the end
and start of two consecutive prescriptions. We qualified all
corticosteroids with the anatomical therapeutic chemical
classification (ATC code) H02AB. Injectable, inhaled, and
topical corticosteroids were excluded. All corticosteroid
doses were converted to “prednisolone equivalents” using
defined daily dose (DDD) [7]. The average observed daily
dose for each subject was calculated by dividing the
cumulative dose dispensed by the number of days of the
total corticosteroid episode. We excluded those who
appeared to use implausible daily doses of prednisolone
(≥100 mg/day prednisolone or equivalent [3]). The initial
prescriber of the corticosteroid was determined from the
Excluded 
 1089 Dose <7.5 mg/day 
 121 Male <70 year and >7.5 and <15 mg/day 
 60 Female <55 year and >7.5 and< 15 mg/day 
Excluded 
7670 different episodes using 
corticosteroid < 90 days  




 27 no birth date 
 36 length of therapy unknown 
 4 sex unknown 
 22 dose≥100mg/day 
692 corticosteroid users met 2002 
Dutch guidelines for osteoporosis 
prophylaxis 
1962 different episodes 




615 different patients  
(first  corticosteroid episode) 
Excluded 
 77 episodes of patients with >1 episode 
Fig. 1 Flowchart of patient
inclusion
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pharmacy data; in The Netherlands both general practi-
tioners (GPs) and specialists prescribe directly.
Co-medication
All co-medications (excluding antibiotics) during the
corticosteroid episode were calculated. Concurrent respira-
tory medications were: inhaled corticosteroids, short/long
acting inhaled β2 agonists, or leukotriene-receptor antago-
nists. Other concurrent medication included: disease-mod-
ifying anti-rheumatic drugs (DMARDs), proton pump
inhibitors (PPI), non-steroidal anti-inflammatory drugs
(NSAIDs), antiplatelets, and vitamin K antagonists (VKA)
or low molecular weight heparins (LMWH).
Statistics
Standard descriptive methods and statistics were used to
characterise the study population using SPSS® version 14
(SPSS, Chicago, IL United States). A logistic regression
model was used to identify factors significantly associated
with the prescribing of a bisphosphonate. Univariate and
multivariate analyses were used to predict which variables
(age; sex; number of co-medication; duration of corticosteroid
use; prescriber of corticosteroid; daily corticosteroid dose;
concomitant PPI, NSAID, DMARD, respiratory medication,
antiplatelets, VKA, and LMWH use) influenced the prescrib-
ing of a bisphosphonate. For the multivariate analysis each
individual variable was adjusted for the remaining variables in
the model as aforementioned. A two-tailed p value ≤0.05 was
considered statistically significant.
Results
We identified 692 different corticosteroid episodes which
met the inclusion criteria for requiring prophylaxis. This
group consisted of 615 different patients (Fig. 1). Of these
615 patients requiring prophylaxis, 267 (43%) received a
bisphosphonate (51% received any prevention). The char-
acteristics of the bisphosphonate and non-bisphosphonate
users are shown in Table 1.
Trends in osteoporosis prevention
Figure 2a shows the use of CIOP-prophylaxis in patients
who require prophylaxis with bisphosphonates according to
Dutch guidelines. From 2001–2005 bisphosphonate use
increased from 38% to 54% (trend p=0.001) and any
treatment increased from 48% to 62% (trend p=0.001).
Figure 2b shows the sex differences in osteoporosis
prevention (2001–2005) in those requiring prophylaxis.
Females received more osteoporosis prevention than males
(72% vs. 45%; p<0.001) in 2005; specifically, females used
more bisphosphonates in 2005 than males (61% vs. 39%;
p=0.002). Bisphosphonate use in females significantly
increased from 40% in 2001 to 61% in 2005 (p=0.001).
For men there was a non-significant increase in any
osteoporosis prevention (p=0.09) or bisphosphonate use
(p=0.20).
Variables influencing the use of bisphosphonates
Multivariate analysis showed that duration of corticosteroid
use >360 days (OR 6.50; 95%CI:3.64–11.60) and DMARD
Table 1 Characteristics of 615 corticosteroid users (July 2001–Dec









Female (%) 187 (70) 188 (54) p<0.001
Mean age (SD) 66.5 (14.2) 69.7 (16.1) p=0.01
Mean dose (SD) 16.3 (9.6) 15.5 (9.3) p=0.31
7.5–15 (%) 158 (59) 218 (63)
>15 109 (41) 130 (37)
Mean length of
therapy (days; SD)
631 (517) 341 (348) p<0.001




GP 90 (47) 157 (55)
Specialist 103 (53) 128 (45)
Mean number of
co-medications** (SD)
5.6 (3.9) 5.3 (3.6) p=0.28
PPI (%) 164 (61) 177 (51) p=0.009
NSAID 133 (50) 122 (35) p<0.001
Antiplatelets 53 (20) 69 (20) p=0.99
VKA/LMWH 53 (20) 83 (24) p=0.24
Resp 83 (31) 156 (45) p=0.001
DMARDs 77 (29) 33 (9) p<0.001
Osteoporosis
prevention (%)
Calcium 105 (39) 24 (7) p<0.001
Vitamin D 14 (5) 5 (1) p=0.01
Calcium and
vitamin Db
67 (25) 12 (3) p<0.001
HRT 4 (1) 7 (2) p=0.76
SERMs 0 0 NA
a bisphosphonate vs. non bisphosphonate user; *three prescribers
unknown + 134 prevalent corticosteroid users (initial prescriber not
retraceable) **excluding the corticosteroid; GP = general practitioner;
PPI = proton pump inhibitors; NSAIDs = non-steroidal anti-
inflammatory drugs; VKA = vitamin K antagonists; LMWH = low
molecular weight heparins; Resp = inhaled medications for asthma/
COPD; DMARDs = disease-modifying anti-rheumatic drugs; HRT =
oral estrogen±progesterone; SERMs = selective estrogen receptor
modulators
b includes activated and non-activated vitamin D
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use (OR 2.55; 95%CI:1.38–4.69) were positive predictors
to the prescribing of bisphosphonates. Use of respiratory
medication (OR 0.48; 95%CI:0.29–0.78) was a negative
predictor for the prescribing of bisphosphonates. Male sex
was a negative predictor in the univariate analysis (OR
0.51; 95%CI:0.37–0.72), but in multivariate analysis
trended towards significance (OR 0.69; 95%CI:0.44–1.09).
Discussion
Our study has described the trends in osteoporosis
prevention in a group of patients in which Dutch guide-
lines recommend bisphosphonates be used independent of
BMD. We have observed improvements in preventive
therapy use in those who fulfil Dutch guidelines. These
improvements are likely to have coincided with the
introduction of specialist Dutch guidelines for osteoporo-
sis and CIOP in 2002. In addition, in March 2005, we
distributed locally produced CIOP prevention guidelines
to family physicians, pharmacists, and specialists. Curtis
et al. [3] recently showed that in the USA there has been a
gradual increase in BMD testing and osteoporosis pro-
phylaxis prescribing in corticosteroid users, although
absolute rates remain low.
Disappointingly we have shown that males are still
significantly less likely to receive osteoporosis prophylaxis
than females. Furthermore, in contrast to females, males
showed no significant improvement from 2001–2005.
Other recent studies have also found that males appear
undertreated more than females [3, 8]. It is possible that
females are given more attention than males because of
their postmenopausal bone loss, which men do not
experience. However, the reasons why men are less treated
remain enigmatic and further study is required to investi-
gate these sex differences.
DMARD users were 2.5 times more likely to receive a
bisphosphonate and users of respiratory medication were
Fig. 2 Trends in prescribing of
osteoporosis prophylaxis in cor-
ticosteroid episodes requiring
bisphosphonates as per Dutch
guidelines. a) All preventive
agents b) Influence of gender
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less than half as likely to receive bisphosphonate prophy-
laxis. We speculate that this may be related to the particular
doctor specialty. If this is true, our data is in agreement
with the recent paper published by Saag et al. [8] who
found rheumatologists were 3.5 times more likely to
prescribe non-estrogen osteoporosis therapy and respiratory
physicians the least likely out of all specialists to prescribe
non-estrogen osteoporosis prevention in long-term cortico-
steroid users.
There are some limitations to our study that require
comment. Firstly, we did not have clinical information on
our patient group such as BMD testing or fracture history.
However, Dutch guidelines recommended all patients
commence biphosphonates if they are on >15 mg or are
receiving >7.5 mg/day and are postmenopausal or >70 years
(male) independent of BMD. We were also unable to
exclude those patients in whom osteoporosis prevention
may be inappropriate, for example, patients suffering from
alcoholism, dementia, and serious renal impairment. How-
ever, given the mean age of our patients we believe this is
also unlikely to affect our overall results. Lastly, we have
obtained data from a specific region (and do not have a
control group) in The Netherlands and therefore our results
may not be generalisable to the entire Dutch population.
However, corticosteroid use in our catchment population
(0.5%) was comparable to other population-based studies
(0.5–0.9%) [9, 10] and our exclusion criteria were
negligible.
Despite our study’s limitations, we believe that post-
menopausal corticosteroid users are now being reasonably
well treated because bisphosphonate use was 61% and any
prophylactic treatment was 72% in 2005. The high use of
prophylaxis in females probably reflects that doctors and
pharmacists are finally recognizing this patient group.
Although it is difficult to define an absolute standard of
care, recognising contraindications as well as patient refusal
or intolerance, we believe that in our population there is
probably scope for further absolute improvement in the use
of bisphosphonates of approximately 10–20% in females
and 30–40% in males.
There are multiple reasons why patients are not receiving
prophylaxis as recently highlighted [11]. Clearly, efforts are
required to address the undertreatment and there have been
interventions educating patients, pharmacists, GPs and
specialists which demonstrated an improvement in CIOP
management [5, 12]. We are prospectively investigating the
effect of a pharmacist recommendation to GPs whose
patients require prophylaxis. Importantly, doctors are
required to list specific reasons why their patients are not
prescribed bisphosphonates, which we hope will allow a
standard of care to be defined so future audits can assess if
CIOP prevention is satisfactory.
Conclusion
We have found that in patients requiring prophylaxis with
bisphosphonates according to Dutch guidelines, prevention
was received in 54% of the cases in 2005. It is clear that there
has been a significant improvement in the treatment of women
who now appear to be reasonably well treated. However, men
are still not receiving prevention to the same degree as
women, and it is now time to focus our attention and address
this issue to identify if they are genuinely neglected.
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